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Abstract 
 
Background:  Cryptococcosis is the third most common invasive fungal infection in 
solid organ transplant (SOT) recipients. There are no nationally representative data 
describing the incidence, risk factors and outcomes of cryptococcosis after SOT. 
 
Methods: We assembled a large cohort of adult SOT recipients using ICD-9 CM billing 
data from HCUP State Inpatient Databases of Florida (2006-2012), New York (2006-
2011) and California (2004-2010).  Demographics, comorbidities, death, and 
cryptococcal infections coded during hospitalization were identified. 
 
Results:  42,634 adults with SOT were identified during the study period. Cryptococcal 
disease was identified in 0.37 % (n=158), of which 44% had meningitis (n=69). Median 
time to diagnosis of cryptococcosis was 464 days (range 4 – 2,393).  The median time to 
onset of cryptococcosis was earlier for lung (191 days; range 7.5 – 1,816), heart (195 
days; range 4 – 1,061) and liver (200 days; range 4 – 1,581) compared to kidney 
transplant recipients (616 days; range 12 – 2,393); P < 0.001 log rank test. Very early–
onset disease (< 30 days after transplantation) more frequently occurred in liver and lung 
transplant recipients. Lung transplant recipients had the highest risk of cryptococcosis 
(HR 2.10; CI 1.21 – 3.60). Cryptococcosis was associated with death (HR 2.29; CI 1.68 – 
3.11), after adjusting for age, type of SOT, prior transplant failure/rejection, diabetes, and 
other comorbidities. 
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Conclusion: Cryptococcosis is rare after SOT but associated with significantly increased 
risk of death.  Lung transplant recipients are at highest risk for cryptococcosis among 
SOT’s. Non-kidney transplants have earlier onset of cryptococcosis and higher risk of 
death compared to kidney transplant recipients.   
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Introduction  
Cryptococcosis is an important opportunistic fungal infection that causes significant 
mortality and morbidity among solid organ transplant (SOT) recipients (1-3).  
Traditionally cryptococcosis is most often associated with human immunodeficiency 
virus (HIV) infection; however, with the advent of effective antiretroviral therapy, the 
majority of cases in developed nations occur among non-HIV infected patients, especially 
organ transplant recipients (4, 5). Among 302 cases of cryptococcosis identified over a 
14-year period from an academic medical center in the southern United States, 28% 
occurred in SOT recipients (4). Results from the Transplant-Associated Infection 
Surveillance Network (TRANSNET), a consortium of 23 U.S. transplant centers and data 
from Prospective Antifungal Therapy Alliance (PATH Alliance), showed that 
cryptococcosis is the third most common invasive fungal infection in SOT recipients, 
after invasive candidiasis and aspergillosis, comprising 8-10% of all invasive fungal 
infections identified in SOT recipients (1, 6). Overall incidence rates of cryptococcosis in 
cohorts of SOT recipients range from 0.2% to 4.1%, depending on the type of organ 
transplanted and the duration of follow-up and has remained stable over the years (1, 3).  
 
 Organ transplantation is a rapidly evolving field with rapid strides in surgical 
techniques, immunosuppression and prophylactic antifungal therapy. Although the 
incidence of invasive candidiasis and aspergillosis in SOT has decreased significantly 
over years the incidence of cryptococcosis has remained stable [ median incidence of 
cryptococcosis was 1.52% (range, 0.27% – 5.3%) among a prior cohort (1950-2000) and 
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1.56% (range, 0.45% – 4.1%) among more recent cohort of SOT recipients (2001 - 
2008)] (3).  
 Cryptococcosis typically occurs late in the post-transplant period, with a median of 
575 days from transplant in the TRANSNET study and 21 months in a multinational 
prospective study among all types of SOT recipients by Singh et al (1, 7) . The time to 
onset of disease was earlier (< 12 months) for the majority of lung and liver transplant 
compared to kidney and heart transplant recipients in a review of published cases of 
cryptococcosis in SOT recipients (8). Mortality rates among all types of SOT recipients 
with cryptococcosis range from 14-19.6% and may approach 50% in SOT recipients with 
meningitis (3, 6, 9). Independent risk factors for death in all types of SOT recipients were 
cryptococcemia, high intracranial pressure and renal failure, while calcineurin-inhibitor 
based immunosuppressive regimens were associated with lower mortality (7) .  
 Studies from academic medical centers contribute to our understanding of 
epidemiology of cryptococcosis and its outcomes in SOT recipients, however they have 
limited generalizability. Cryptococcosis identified and managed in community hospitals 
after patients have transitioned away from transplant centers may have been missed, 
especially with the prolonged time to onset after transplant. There are no population-level 
data describing the epidemiology of cryptococcosis and cryptococcal meningitis post-
transplantation. We assembled a large and more representative cohort of SOT recipients 
from multiple hospitals using the longitudinal Agency for Healthcare Research and 
Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP) State Inpatient 
Databases (SID) to study the epidemiology of cryptococcosis and cryptococcal 
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meningitis. The SID contain demographic and billing data that capture inpatient 
diagnoses and procedures through International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) coding. This approach allowed us to follow 
a large number of patients over a long period of time and identify cryptococcosis and 
cryptococcal meningitis regardless of whether patients were treated in the index 
transplant hospital or a different hospital.  
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Methods: 
Study design and patient population.  We performed a retrospective cohort study of 
adults aged 18 years and older who underwent kidney, lung, liver, heart, pancreas, or 
intestine SOT, identified by ICD-9-CM procedure codes (55.69, 50.59, 37.51, 33.50, 
33.51, 33.52, 33.6, 52.80, 52.86, 46.97) from 2004 to 2010 in California, 2006 to 2012 in 
Florida, and 2006 to 2011 in New York. These states and years were chosen based on the 
availability of patient-level encrypted identifiers to link admissions within and across 
hospitals over time and the population diversity of these states. We chose the cohort 
inception years to allow one year of prior data to identify comorbidities. Only the first 
transplant during the study period was included for all patients.  We excluded patients 
who lived in states other than the one where transplantation was performed, were coded 
for cryptococcosis and cryptococcal meningitis within 1 year before transplantation, or 
died on the day of transplant.   This study was considered exempt by the Washington 
University School of Medicine Human Research Protection Office. 
 
Demographic data, comorbidities and follow-up.  Demographic characteristics of the 
study population were determined during the transplant admission.   Comorbidities were 
identified using the Elixhauser classification and ICD-9-CM diagnosis codes within one 
year before and during the transplant hospitalization (10). Comorbidities that were the 
primary reason leading to transplant were excluded (e.g., renal failure in kidney 
transplant, liver disease in liver transplants). Transplant failure or rejection episodes were 
identified during readmissions but considered a potential risk factor for cryptococcosis 
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only if it was identified prior to its onset. Inpatient readmissions were identified using the 
encrypted patient-level identifier.   Dates of onset of cryptococcosis, cryptococcal 
meningitis and transplant failure or rejections were estimated to be midpoint of the stay if 
they were coded during the initial transplant hospitalization. For events identified during 
readmissions the date of admission was considered the date of onset. Prior transplantation 
was identified by a procedure code for SOT in the year prior to transplantation (only in 
the year reserved for comorbidities) or by a V-code to indicate prior transplant (V42.0, 
V42.7, V42.1, V42.6, V42.83, and V42.84). Transplant failure or rejection was not 
considered if it was coded during the transplant hospitalization in an individual with a 
history of SOT. Outcomes identified during the SOT hospitalization and during hospital 
readmissions were newly-coded cryptococcosis (ICD-9-CM diagnosis code 117.5) and 
cryptococcal meningitis (ICD-9-CM diagnosis code 321.0).  ICD-9-CM diagnosis codes 
for septicemia, pneumonia, surgical site, and skin and soft tissue infection assigned 
during the admission coded for cryptococcosis were used to characterize the site of 
cryptococcal infection (codes listed in the Appendix).  
 
Statistical analysis.  Descriptive statistics were used to describe the demographic and 
clinical characteristics of the study population.  Potential risk factors for cryptococcosis 
and inpatient death were analyzed using univariable and multivariable Cox proportional 
hazards models. To create a censor date, the transplant date was estimated as the 15
th
 day 
of the admission month for CA and NY, and the midpoint of the discharge quarter for FL 
(FL SID does not provide an admission month). In the risk factor analysis for 
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cryptococcosis, patients were censored at inpatient death, or maximum follow-up.  The 
proportional hazards assumption was evaluated for each variable using visual inspection 
of log-log survival curves and the correlation between Schoenfeld residuals and ranking 
of individual failure times (11). Variables were specified by selecting clinically 
meaningful factors that could potentially be associated with cryptococcosis and we 
sequentially eliminated variables with highest P values to arrive at a parsimonious model, 
followed by assessment of confounding to arrive at the final model.   To evaluate whether 
the risk of death with and without cryptococcosis varied with time we used a heavy-side 
function to assess differential risk within one year and after one year of transplant (12).  
Statistical significance was set at p < 0.05.  All analyses were performed using SAS 
Enterprise Guide 5.1 (Cary, North Carolina). 
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Results:  
Patient characteristics 
The final study population consisted of 42,634 adult SOT recipients.  A total of 63.7% 
had kidney transplantation, followed by 21.1% liver, 7.2% heart, and 5.2% lung 
transplants. Other or multiple organs were transplanted in 2.4% of the SOT patients 
(pancreas, intestine or multi-organ). The mean age at the time of transplant was 51.7 
years; 62.6% were males, 51.2% were white, 21.1% were Hispanic, 76.3% lived in large 
metropolitan areas, and 15.8% had Medicaid or self-pay listed as primary insurance.    
Commonly identified comorbidities were, diabetes mellitus (37.5%), renal failure (12.0 
%) and chronic lung disease (10.1%). 1,492 patients (3.5%) had history of a prior organ 
transplant(s).  The median duration of follow-up after SOT was 1295 days (range 1-3075 
days). 
Cryptococcal Infections  
One hundred fifty-eight patients were coded for cryptococcosis (0.37%) after SOT. There 
was no significant difference in the incidence of cryptococcosis identified between the 
three states (0.35 % in CA, 0.37% in FL and 0.41 % in NY; P = 0.661). Sixteen of 158 
patients were coded for cryptococcosis during the index transplant hospitalization.   A 
total of 69 (44%) patients were identified with meningitis. Of the remaining patients with 
non-meningeal cryptococcosis, 41 (46.06%) were coded for pneumonia and 19 (21.34%) 
additional patients were coded for septicemia, skin and soft tissue or surgical site 
infection.  Eighty-nine (0.32%) patients with cryptococcosis were identified after kidney 
transplant, 40 (0.44%) after liver, 15 (0.66%) after lung, and 13 (0.42%) after heart 
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transplantation. Twenty-six percent (38/158) of patients with cryptococcosis identified at 
readmission were treated at a hospital different from the index transplant surgery 
hospital. Eighty-three percent (57/69) of patients with cryptococcal meningitis had a 
procedure code for a lumbar puncture during the admission compared to 41% (36/89) of 
patients coded for cryptococcosis without meningitis (P < 0.001).   
Lung transplant recipients had the highest risk of cryptococcosis compared to other organ 
transplant recipients, with a HR of 2.10 after adjusting for age and underlying 
comorbidities (Table 1). Increasing age, diabetes and having Medicaid or no health 
insurance were also risk factors for cryptococcosis in the multivariable Cox model (Table 
2).  
The median time to diagnosis of cryptococcosis from the date of transplant was 464 days 
(range 4 – 2,393). The median time to onset of disease was earlier after lung (191 days; 
range 7.5 – 1816), heart (195 days; range 4-1,061) and liver (200 days; range 4-1,581) 
than kidney transplant (616 days; range 12 – 2,393) (P < 0.001, Kruskal-Wallis test, 
Figure 1). 
Very early versus later onset cryptococcosis 
Very early–onset disease (cryptococcosis occurring within 30 days after transplantation) 
developed in 16 (10.1%) of 158 patients (median 10.7 days, range 4 - 23) after transplant 
while later onset cryptococcosis more than 30 days after transplant occurred in the 
remaining 142 patients (median 515 days, range 32 – 2,393).  The proportion of patients 
with very early onset disease among liver or lung transplants was significantly higher 
than other transplants (P <0.001, Fischer’s exact test). However inpatient mortality did 
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not differ between the patients with very early onset vs. later-onset cryptococcosis (P = 
1.000; Fischer’s exact test).  
Inpatient Mortality in patients with cryptococcosis 
Forty-one of 158 (26.0%) patients with cryptococcosis died during the study period in-
hospital versus 3,879 of 42,476 (9.1%) without cryptococcosis (HR 2.57; P < 0.001, 
Table 3 and Figure 2). Eighteen of 69 (26.1%) patients with cryptococcal meningitis 
died (HR 2.54, P < 0.001 compared to uninfected SOT recipients). In multivariable 
analysis cryptococcosis was associated with 2.3-fold increased risk of inpatient mortality 
(P < 0.001), adjusting for age, type of transplant, prior graft rejection/failure and several 
comorbidities (Table 3).  There was no increased mortality risk with cryptococcosis 
during the first year after transplant (HR 1.39; P = 0.257); but there was a 3.2-fold 
increased risk of mortality more than one year after transplant (P < 0.001, Figure 2). The 
risk of death was highest for lung, followed by liver, heart and other transplants 
compared to renal transplant. Increasing age, prior transplant failure/rejection, congestive 
heart failure, liver disease, having Medicaid or no health insurance, and several other 
comorbidities were independent risk factors for in-hospital death (Table 3).  The median 
time to death from diagnosis of cryptococcosis was 87.5 days (range 3 – 2,792). The 
median time to death from transplant was 637 days (range 32 – 2807) in patients with 
cryptococcosis and 359 days (range 1 – 2,858) in patients without cryptococcosis (P < 
0.001, log rank test).  
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Discussion 
We found that cryptococcal infections were rare, but associated with significant mortality 
in a large diverse population of SOT recipients from three U.S. states. The overall 
incidence of cryptococcosis was 0.37%, similar to the 12-month incidence of 0.2% 
reported in the TRANSNET study (1). Prior studies have found that 44 – 60% of SOT 
recipients with cryptococcosis developed CNS involvement (2,7,13). We found that 
meningitis was coded in 44% of the SOT recipients with cryptococcosis. The Infectious 
Diseases Society of America guidelines recommend evaluating for meningitis by lumbar 
puncture in SOT recipients with positive cryptococcal antigen test and in all 
immunosuppressed patients with pulmonary cryptococcosis (14). The proportion of 
patients coded for a lumbar puncture was significantly lower among the patients with 
cryptococcosis without meningitis compared to those patients coded for cryptococcal 
meningitis. The slightly higher proportion of patients without cryptococcal meningitis 
when compared to previous studies could be due to an error in additional coding for 
meningitis, or an error in ascertainment wherein an active search for CNS disease was not 
done in these patients (2,7). Among patients with non-meningeal cryptococcosis, the 
commonest site of involvement was pulmonary followed by septicemia and skin / soft 
tissue involvement, similar to the clinical presentations reported in prior cohorts of SOT 
recipients (2,3). 
The majority of cases of cryptococcosis are late infections and considered to represent 
reactivation of latent infection in the recipient (15). The median time to cryptococcal 
disease from transplantation in our study (464 days) was consistent with the findings of 
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TRANSNET study (575 days) (1). Very early onset of cryptococcosis (within one month 
after transplant) is rare, and was reported in 5% of 175 SOT recipients with 
cryptococcosis by Sun et al (16). We found 10% of SOT recipients were coded for very 
early onset disease. Similar to the finding in the study by Sun et al., the majority of very 
early onset cryptococcal infection in our study occurred in liver and lung transplant 
recipients (16). These very early onset infections may reflect either undetected pre-
transplant or donor-derived infections. Albeit rare, this should prompt clinicians to 
consider cryptococcosis in the evaluation of very early onset infections.  
In this study lung transplant recipients had the highest risk for cryptococcosis, followed 
by liver and heart transplant recipients. Kidney transplant recipients had the lowest risk. 
This has not been reported previously in the literature. The median time to onset of 
cryptococcosis after transplant was earlier for lung, heart and liver (<1 year) compared to 
kidney transplant recipients (1.7 years). This was similar to the findings by Husain et al., 
where the median time to onset of cryptococcosis was 35 months for kidney and 25 
months for heart, compared to 8.8 and 3 months for liver and lung transplant recipients 
(8). The higher risk and earlier onset of disease may reflect the greater intensity of 
immunosuppression with a higher risk of reactivation disease in the non-kidney 
transplant populations.  
Twenty-six percent of patients with cryptococcosis died in-hospital versus 9.1% without 
disease over a median follow up time of 3.5 years in this large cohort of SOT recipients. 
The 90-day mortality rate (13.3%) in our study was very similar to that reported in a 
multicenter study of 111 SOT recipients with cryptococcosis by Singh et al in the modern 
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era of effective antifungal therapy (14%) (7).   In our multivariable model, cryptococcosis 
was significantly associated with over a 2-fold increase risk of death.   Lung, liver and 
heart transplant recipients were at higher risk for death compared to renal transplant 
recipients after adjusting for age, cryptococcosis and other comorbidities.  Insurance 
coverage affected risk of death with patients with Medicaid or no health insurance at 
higher mortality risk.  
The strengths of this study are the large cohort size, the long duration of follow up that 
allowed capture of late occurring infections, and identification of cryptococcosis treated 
in a hospital other than the transplant center. Twenty-six percent of infections were 
diagnosed in a hospital other than the patient’s primary transplant center. Use of large 
administrative databases, such as the SID adds to our understanding of outcomes of rare 
diseases among hospitalized patients and supplements detailed single- and multi-center 
studies. However, there are several limitations. The ICD-9-CM diagnosis codes used to 
identify cryptococcosis in this study have not been validated, although the code for 
cryptococcal meningitis has been used to describe the epidemiology of disease (17). A 
validation study of ICD-9 diagnosis codes for several severe infections report positive 
predictive values >80% (18). Another limitation is that the data source used in this study 
contains only demographic and inpatient hospital ICD-9-CM billing data and does not 
have microbiology or other laboratory test results or data on antifungal or immune 
suppressive medications.  
In summary, this is the first study that provides population-level information on the 
epidemiology of cryptococcosis after SOT in the current era. Cryptococcosis though rare, 
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was associated with significant mortality in this population. Lung, liver and heart 
transplant recipients were at higher risk for cryptococcosis compared to kidney transplant 
recipients. Cryptococcosis remains an important threat in SOT recipients and we need 
better management strategies and prophylactic and screening algorithms especially in 
liver and lung transplant recipients at risk of very early onset disease as subject of future 
research.   
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Table 1. Univariable risk factors for Cryptococcosis in patients with and without Cryptococcosis among 42,634 solid organ transplant 
recipients. 
                    No. (%)of patients  HR (95% CI) p 
 With Cryptococcosis 
 (n = 158) 
Without Cryptococcosis 
(n= 42,476) 
  
Age     
   18-40 years 16 (10.1) 8456 (19.9) 1  
   41-50 years 35 (22.2) 8925 (21.0) 2.07 (1.14 – 3.74) 0.016 
   51-60 years 50 (31.6)  13119 (30.9) 2.04 (1.16 – 3.58) 0.013 
   60-70 years 48 (30.4) 9969 (23.5) 2.67 (1.52 – 4.71) 0.007 
  >70 years  <11 2007 (4.7) 2.50 (1.10 – 5.65) 0.028 
Race      
White 74 (46.8) 20926 (49.3) 1  
Black 17 (10.7) 6363 (14.9) 0.78 (0.46- 1.34) 0.359 
Hispanic 42 (26.6) 8981 (21.1) 1.36 (0.93 – 1.98) 0.114 
Asian or Pacific Islander 13 (8.2) 3364 (7.9) 1.11 (0.62- 2.02) 0.728 
Other or missing 12 (7.6) 2842 (6.7) 1.31 (0.71-2.42) 0.382 
Female Sex 54 (34.1) 15882 (37.4) 0.95 (0.89 – 1.01) 0.596 
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Type of Insurance     
      Private/Medicare/Others 133 (84.2) 38489 (90.6) 1  
      Medicaid/Self-pay 25 (15.8) 3987 (9.4) 1.80 (1.17 – 2.75) 0.007 
Income quartile      
    0-25
th
  73 (46.2) 13081 (30.8) 2.10 (1.30 -3.33) 0.002 
    51-75th 26 (16.5) 10115 (23.8) 1.05 (0.60 -1.83) 0.857 
    76 -100
th
 24 (15.2) 9913 (23.3) 1  
Type of transplant     
Kidney 89 (56.3) 27129 (63.9) 1  
Liver 40 (25.3) 8970 (21.1) 1.32 (0.91 – 1.92) 0.142 
Lung 15 (9.5) 2223 (5.2) 2.06 (1.19 – 3.57) 0.009 
Heart 13 (8.2) 3059 (7.2) 1.29 (0.72 – 2.30) 0.397 
Others (multi-organ) <11 1095 (2.6) 0.27 (0.04 – 1.93) 0.191 
Prior transplant failure / rejection 85 (53.8) 22475 (52.9) 0.50 (0.16 – 1.59) 0.244 
Other comorbidities     
Diabetes mellitus  86 (54.4) 15898 (37.4) 2.03 (1.48 – 2.78) 0.001 
Renal failure 16(10.1) 5110 (12.0) 0.84 (0.52 – 1.41) 0.512 
Chronic pulmonary disease   19 (12.0) 4308 (10.1) 1.20 (0.74 – 1.93) 0.421 
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Congestive Heart Failure   16 (10.1) 4127 (9.7) 1.02 (0.63 – 1.71) 0.930 
Liver disease   10 (6.3) 2243 (5.3) 1.22 (0.65 – 2.33) 0.532 
Connective tissue disorder <11 1923 (4.5) 0.56 (0.20 – 1.51) 0.252 
      Prior transplantation <11 1489 (3.5) 0.51 (0.16 – 1.59) 0.243 
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Table 2.  Multivariable Cox proportional hazard model of risk factors for cryptococcosis 
Risk factor HR (95% CI) p 
Age  
   18-40 years 
   41-50 years 
   51-60 years 
   60-70 years 
   >70 years 
 
1.00 
1.92 (1.06 – 3.48) 
1.78 (1.01 – 3.13) 
2.28 (1.22 – 3.86) 
2.41 (1.03 – 4.95) 
 
 
0.030 
0.046 
0.007 
0.041 
Type of transplant   
Kidney 1.00  
Liver 1.16 (0.78 – 1.71) 0.466 
Lung 2.10 (1.21 – 3.60)  0.009 
Heart 1.15 (0.63 – 2.07) 0.645 
Others (multi-organ) 0.23 (0.03 – 1.64) 0.142 
Diabetes mellitus 1.95 (1.41 – 2.69) <0.001 
Medicaid/Self pay 1.99 (1.27 – 3.11) 0.002 
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Table 3.  Cox proportional hazard model of risk factors for death in 42,634 solid organ transplant recipients. 
 Univariable analysis Multivariable analysis 
Risk factor HR (95% CI) p HR (95% CI) p 
Cryptococcosis 
Cryptococcal Meningitis 
Age  
   18-40 years 
   41-50 years 
   51-60 years 
   60-70 years 
   >70 years 
  2.57 (1.89 – 3.50) 
    2.54 (1.60 – 4.04)  
 
    1.00 
    1.46 (1.30 – 1.65) 
   2.01(1.81 – 2.24) 
    2.77 (2.48 – 3.09) 
    3.32 (2.87 – 3.85) 
<0.001 
<0.001 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
2.29 (1.68 – 3.11) 
 
 
 
1.36 (1.19 – 1.53) 
1.60 (1.43 – 1.80) 
2.29 (2.04 – 2.57) 
3.70 (3.14 – 4.30) 
<0.001 
 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
Female sex 0.95 (0.89 – 1.01) 0.596   
Type of transplant     
Kidney 1.00   1.00  
Liver 2.67 (2.47 – 2.87) <0.001 2.47 (2.26 – 2.71) <0.001 
Lung 4.86 (4.41 – 5.37) <0.001 3.68 (3.28 – 4.12) <0.001 
Heart 2.47 (2.21 – 2.76) <0.001 2.32 (2.11 – 2.65) <0.001 
Others (multi-organ) 3.35 (2.88 – 3.89) <0.001 2.21 (1.86 – 2.65) <0.001 
Type of Insurance     
      Medicaid/Self-pay 1.46 (1.28 – 1.56) <0.001 1.24 (1.13 - 1.37) <0.001 
Prior transplant failure / rejection 2.66 (2.46 – 2.86) <0.001 2.53 (2.38 – 2.77) <0.001 
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Other comorbidities     
Diabetes mellitus 1.27 (1.20 – 1.36) <0.001 1.14 (1.07 – 1.21) 0.001 
Renal failure 1.66 (1.53 – 1.80) <0.001   
Chronic pulmonary disease 1.31 (1.20 – 1.44) <0.001   
Obesity 1.04 (0.94 – 1.15) 0.484   
Congestive heart failure 
Liver disease 
Connective tissue disorder 
Solid tumors  
Hypertension 
Hematological malignancies 
Cancer with metastasis 
Valvular heart disease 
Depression 
Pulmonary circulation disorder 
Weight loss 
Peripheral vascular disease 
Electrolyte disorders 
Psychoses 
Drug abuse 
Neurological disorders 
1.68 (1.54 – 1.83) 
1.41 (1.24 – 1.60) 
0.83 (0.70 – 0.98) 
 1.51 (1.12 – 2.04) 
0.52 (0.49 - 0.56) 
1.65 (1.11 – 2.48) 
1.95 (1.27 – 2.99) 
1.52 (1.39 – 1.66) 
1.38 (1.26 – 1.52)  
2.12 (1.95 – 2.31) 
    2.07(1.90 – 2.27) 
1.34 (1.38 – 1.69) 
1.51 (1.42 – 1.62)  
1.48 (1.26 – 1.75) 
1.57(1.33 –  1.81) 
1.20 (1.06 – 1.36) 
<0.001 
<0.001 
0.020 
0.006 
<0.001 
0.013 
0.002 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.002 
1.58 (1.47 – 1.73) 
1.22 (1.05 – 1.42) 
 
 
0.87 (0.80 – 0.94) 
 
 
 
 
 
1.22 (1.11 – 1.34) 
1.46 (1.32 – 1.62) 
1.18 (1.11 – 1.26) 
1.21 (1.02 – 1.42) 
1.20 (1.05 – 1.39) 
 
<0.001 
0.007 
 
 
<0.001 
 
 
 
 
 
<0.001 
<0.001 
<0.001 
0.022 
0.006 
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Prior transplantation 1.23 (1.05 – 1.43) 0.008 
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Figure 1: Time to onset of cryptococcosis in days, stratified by type of transplant. 
 
 
 
Boxes represent values within the 25th–75th percentiles (interquartile range), and horizontal lines represent 
the median and the diamonds the mean values.  Error bars indicate the maximum and minimum observation 
below the upper and lower fences (1.5 IQR) and circles the maximum observations. 
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Figure 2: Time to death in days, in a cohort of adult solid organ transplant recipients, stratified by the presence or absence of 
cryptococcosis. 
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APPENDIX.  Diagnosis Codes Used in Combination to Identify Septicemia, 
Pneumonia, Surgical Site Infection, and Skin and Soft Tissue Infections  
 
Diagnosis  ICD-9-CM Diagnosis Code
 
Septicemia 038.8, 038.9, 790.7 
Pneumonia 483.8, 484.7, 484.8, 485 ,486, 510, 510.9, 513.0 
Surgical Site Infection 998.5, 998.51, 998.59 
Skin and Soft Tissue Infection 5673.1, 680.0 -680.9, 681.00 – 681.02, 681.10, 
681.11, 681.9, 682.0- 682.9, 683, 684, 685.0,  
686.0, 686.00, 686.01, 686.09, 686.1, 686.8, 
686.9, 675.00- 675.04, 675.10 – 675.14, 675.80 
– 675.84, 675.90 – 675.94, 705.83, 727.89, 
728.0, 728.86 
 
 
 
 
